Kết quả của chương trình hóa trị liệu giống leukemia lymphoblast với xạ trị trung thất theo nguy cơ và cấy ghép tế bào gốc cho bệnh nhân trưởng thành mắc lymphoma lymphoblast

Brunning RD, Borowitz M, Matutes E, Head D, Flandrin G, Swerdlow SH et al (2001) Precursor B lymphoblastic leukaemia/lymphoma (precursor B-cell acute lymphoblastic leukaemia). In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 111–114 Brunning RD, Borowitz M, Matutes E, Head D, Flandrin G, Swerdlow SH et al (2001) Precursor T lymphoblastic leukaemia/lymphoma (precursor T-cell acute lymphoblastic leukaemia). In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 115–117 Hoelzer D, Gokbuget N (2002) Treatment of lymphoblastic lymphoma in adults. Best Pract Res Clin Haematol 15(4):713–728 Slater DE, Mertelsmann R, Koziner B, Higgins C, McKenzie S, Schauer P, Gee T, Straus D, Kempin S, Arlin Z et al (1986) Lymphoblastic lymphoma in adults. J Clin Oncol 4(1):57–67 Morel P, Lepage E, Brice P, Dupriez B, D'Agay MF, Fenaux P, Gosselin B, Bauters F, Gisselbrecht C (1992) Prognosis and treatment of lymphoblastic lymphoma in adults: a report on 80 patients. J Clin Oncol 10(7):1078–1085 Zinzani PL, Bendandi M, Visani G, Gherlinzoni F, Frezza G, Merla E, Manfroi S, Gozzetti A, Tura S (1996) Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. Leuk Lymphoma 23(5–6):577–582 Bouabdallah R, Xerri L, Bardou VJ, Stoppa AM, Blaise D, Sainty D, Maraninchi D, Gastaut JA (1998) Role of induction chemotherapy and bone marrow transplantation in adult lymphoblastic lymphoma: a report on 62 patients from a single center. Ann Oncol 9(6):619–625 Hoelzer D, Gokbuget N, Digel W, Faak T, Kneba M, Reutzel R, Romejko-Jarosinska J, Zwolinski J, Walewski J (2002) Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood 99(12):4379–4385 Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H (2004) Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood 104(6):1624–1630 Neth O, Seidemann K, Jansen P, Mann G, Tiemann M, Ludwig WD, Riehm H, Reiter A (2000) Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: clinical features, treatment, and results in trials NHL-BFM 86 and 90. Med Pediatr Oncol 35(1):20–27 Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H (2000) Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 95(2):416–421 Mora J, Filippa DA, Qin J, Wollner N (2003) Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer 98(6):1283–1291 Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cave H, Dombret H, Fielding AK, Foa R, Gokbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ (2010) Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008. Leukemia 24(3):521–535 Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, Campana D (2009) Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group. J Clin Oncol 27(21):3533–3539 Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Rossi G, Borlenghi E, Pogliani EM, Terruzzi E, Fabris P, Cassibba V, Lambertenghi-Deliliers G, Cortelezzi A, Bosi A, Gianfaldoni G, Ciceri F, Bernardi M, Gallamini A, Mattei D, Di Bona E, Romani C, Scattolin AM, Barbui T, Rambaldi A (2009) Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 113(18):4153–4162 Bassan R, Pogliani E, Lerede T, Fabris P, Rossi G, Morandi S, Casula P, Lambertenghi-Deliliers G, Vespignani M, Izzi T, Coser P, Corneo G, Barbui T (1999) Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. Haematologica 84(12):1088–1093 Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244 Langerak AW, Szczepanski T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ (1997) Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 11(12):2192–2199 Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ, Connors JM (2007) Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol 18(3):535–540 Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Ferme C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V (2006) High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia 20(5):814–819 Le Gouill S, Lepretre S, Briere J, Morel P, Bouabdallah R, Raffoux E, Sebban C, Lepage E, Brice P (2003) Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials. Leukemia 17(11):2220–2224 Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A (2006) Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 24(3):491–499 Shah AB, Hudson MM, Poquette CA, Luo X, Wilimas JA, Kun LE (1999) Long-term follow-up of patients treated with primary radiotherapy for supradiaphragmatic Hodgkin's disease at St. Jude Children's Research Hospital. Int J Radiat Oncol Biol Phys 44(4):867–877 Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak A, Ben-Arie Y, Bar-Shalom R, Israel O (2010) (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51(1):25–30 Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui CH, Evans WE (1996) Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 97(1):73–80 Galpin AJ, Schuetz JD, Masson E, Yanishevski Y, Synold TW, Barredo JC, Pui CH, Relling MV, Evans WE (1997) Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 52(1):155–163 Soslow RA, Baergen RN, Warnke RA (1999) B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 85(12):2648–2654 Maitra A, McKenna RW, Weinberg AG, Schneider NR, Kroft SH (2001) Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature. Am J Clin Pathol 115(6):868–875 Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ (2003) A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood 101(7):2476–2482 Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH (2001) High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol 19(11):2927–2936 Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL Jr (2006) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 12(1):1–30 Bradstock KF, Kerr A (1985) Immunological detection of covert leukaemic spread in mediastinal T-cell lymphoblastic lymphoma. Leuk Res 9(7):905–911